Bounce Mobile Systems, Inc.
BNCM
Other OTC0.01
USD
+0.00
- -
Bounce Mobile Systems, Inc.
BNCM
(Other OTC)
Recent
price
0.01
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Bounce Mobile Systems, Inc. (BNCM) operates as a healthcare company focused on the development, distribution, and trading of pharmaceutical products, medical supplies, equipment, and food supplements primarily in Asia and the Philippines. The company offers medical devices and machines including cardiovascular ultrasounds, needleless connectors and IV lines, and ambulatory/PCA infusion pumps for critical care, anti-infectives, and anesthesia, alongside after-sales services and sales through an online drugstore; it provides over 30 FDA-approved hospital products across therapeutic areas such as oncology and ICU needs, with recent launches of 11 new pharmaceutical products in the first half of 2024. Founded in 2017 and headquartered in New York, New York, Bounce Mobile Systems conducts operations through subsidiaries like DELEX Healthcare Group Inc., DLX Holdings Inc. (established 2009), DELEX Pharma International Inc. (ISO 9001:2015 certified and ranked third-largest national pharma company in Philippine hospital channels by IQVIA), and JMN Brothers Pharma Limited, Inc., which it acquired in 2022 to expand into women's health and beauty products; it maintains over 100 sales and marketing teams, supplies 900 pharmacies and hospitals, and partners with international firms from the US and Germany like Amsino, Masimo, and Verathon for medical devices expected to contribute 30% of revenue. In July 2024, the company completed a transformative merger with DELEX Healthcare Group Inc., transferring management and assets while unveiling post-merger growth plans including new product lines, expansion of DELEX pharmacies to 60 stores, broader distribution networks, and strategic partnerships with manufacturers and healthcare providers; it passed ISO 9001:2015 re-certification in July 2024 and hosts DELEX ICU Forums reaching nearly 200,000 global healthcare professionals.